Related Headline News and Top Stories
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib - Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (egfr). however, about 10 percent of patients have a rapid and often dramatic clinical response.
Recomended News to Read
USDAILY – China’s police ministry on Sunday said 88 fugitives wanted on charges of corruption and other economic offenses have been extradited or returned on their own from the United States and other countries in the midst of an anti-graft crackdown. One fugitive spent 14 years in Canada and was accused of embezzling 60 million […]
USDAILY – MUMBAI, India — Global stock markets were uninspired by an upbeat report on the U.S. economy, with most drifting lower Thursday after the U.S. Federal Reserve said it would make further cuts to its monetary stimulus as expected. Investors are now reckoning with an expiry date for the lavishly easy monetary policy that has […]